401 related articles for article (PubMed ID: 29653557)
21. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.
Guaraná M; Soares A; Daumas A; Biasoli I; Solza C
Hematol Transfus Cell Ther; 2022; 44(3):321-327. PubMed ID: 33483290
[TBL] [Abstract][Full Text] [Related]
22. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
[TBL] [Abstract][Full Text] [Related]
23. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
24. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
25. [Health-related productivity of the Hungarian population. A cross-sectional survey].
Péntek M; Beretzky Z; Brodszky V; Szabó JA; Kovács L; Kincses Á; Baji P; Zrubka Z; Rencz F; Gulácsi L
Orv Hetil; 2020 Sep; 161(36):1522-1533. PubMed ID: 32886627
[TBL] [Abstract][Full Text] [Related]
26. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
27. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of the MPN Landmark survey for impact and perceptions of treatment goals among Chinese physicians and myeloproliferative neoplasm patients].
Xu ZF; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):570-575. PubMed ID: 32810964
[No Abstract] [Full Text] [Related]
29. Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis.
Morrisroe K; Stevens W; Huq M; Sahhar J; Ngian GS; Zochling J; Roddy J; Proudman SM; Nikpour M;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):130-137. PubMed ID: 28516877
[TBL] [Abstract][Full Text] [Related]
30. Impact of Endometriosis on Fatigue and Productivity Impairment in a Cross-Sectional Survey of Canadian Women.
Soliman AM; Rahal Y; Robert C; Defoy I; Nisbet P; Leyland N; Singh S
J Obstet Gynaecol Can; 2021 Jan; 43(1):10-18. PubMed ID: 32978082
[TBL] [Abstract][Full Text] [Related]
31. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study.
Yao Y; Jørgensen AR; Thomsen SF
Int J Dermatol; 2020 Mar; 59(3):333-340. PubMed ID: 31736064
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home.
Soliman AM; Coyne KS; Gries KS; Castelli-Haley J; Snabes MC; Surrey ES
J Manag Care Spec Pharm; 2017 Jul; 23(7):745-754. PubMed ID: 28650252
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
Buono JL; Carson RT; Flores NM
Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis.
Ümit E; Baysal M; Kırkızlar HO; Demir AM
Turk J Haematol; 2024 May; ():. PubMed ID: 38801033
[TBL] [Abstract][Full Text] [Related]
35. Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey.
Yu J; Paranagama D; Parasuraman S
PLoS One; 2020; 15(12):e0243562. PubMed ID: 33382745
[TBL] [Abstract][Full Text] [Related]
36. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
37. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
38. Approach to MPN Symptom Assessment.
Geyer H; Mesa RA
Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
[TBL] [Abstract][Full Text] [Related]
39. Impact of binge eating disorder on functional impairment and work productivity in an adult community sample in the United States.
Pawaskar M; Witt EA; Supina D; Herman BK; Wadden TA
Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28741812
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
